NASDAQ
20.12.24
21:52 Uhr
2,810 US-Dollar
+0,010
+0,36 %
+0,36 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.12. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 79 | GlobeNewswire (Europe) | MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 08.11. | TELA Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 86 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction... ► Artikel lesen | |
| 25.10. | Insider Buying: TELA Bio, Inc. (NASDAQ:TELA) Insider Acquires 6,666 Shares of Stock | 1 | MarketBeat | ||
| 24.10. | Vertriebsleiter von Tela Bio, Gregory Firestone, erwirbt Aktien im Wert von 14.998 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.10. | TELA Bio COO und CFO Roberto Cuca erwirbt Aktien im Wert von 144.999 US-Dollar | 2 | Investing.com Deutsch | ||
| 24.10. | TELA Bio's SWOT analysis: innovative medtech firm faces growth hurdles | 1 | Investing.com | ||
| 23.10. | Piper Sandler hält an Overweight-Bewertung für TELA Bio-Aktien fest | 1 | Investing.com Deutsch | ||
| 23.10. | Piper Sandler maintains Overweight rating on TELA Bio shares | 2 | Investing.com | ||
| 23.10. | TELA Bio, Inc.: TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| 22.10. | TELA Bio announces public offering of stock and warrants | 3 | Investing.com | ||
| 22.10. | TELA Bio announces public offering of common stock, pre-funded warrants | 1 | Seeking Alpha | ||
| 22.10. | TELA Bio, Inc.: TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 22.10. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | TELA Bio stock plunges to 52-week low at $2.31 amid market challenges | 1 | Investing.com | ||
| 10.10. | TELA Bio-Aktie stürzt auf 52-Wochen-Tief von 2,31 US-Dollar | - | Investing.com Deutsch | ||
| 04.10. | Demystifying TELA Bio: Insights From 6 Analyst Reviews | 1 | Benzinga.com | ||
| 24.09. | TELA Bio-Aktie stürzt auf 52-Wochen-Tief von 2,4 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.09. | TELA Bio stock plunges to 52-week low at $2.4 amid market challenges | 1 | Investing.com |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ARVINAS | 18,480 | +3,65 % | Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy | NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE), Tuesday announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of Vepdegestrant in combination... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,36 % bei einem Aktienkurs von 2,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.
